Discover Summit Therapeutics' Q1 2025 milestones, including ivonescimab progress, the global HARMONi trial, and strategic oncology collaborations.

The 'cell of origin' of the second most common lung cancer and the way that it becomes dominant in the lung have been discovered, in a new study in mice and humans from researchers at UCL, the ...